Status:
COMPLETED
Subcutaneous Testosterone Project
Lead Sponsor:
University of British Columbia
Collaborating Sponsors:
Vancouver Coastal Health Research Institute
Conditions:
Gender Dysphoria
Eligibility:
MALE
19-59 years
Phase:
PHASE1
PHASE2
Brief Summary
For people who identify as transgender, there is a strong sense that they were born into the wrong body and that their outward looking body does not match how they truly feel about themselves. They fe...
Detailed Description
Rationale: In caring for transgender males (born female but identify as male), intramuscular (IM) testosterone is considered standard of care if they elect therapy to transition. Yet, IM testosterone...
Eligibility Criteria
Inclusion
- Transgender males or identifying along the male spectrum
- Currently on stable doses of weekly IM testosterone
- Using either Testosterone cypionate or enanthate
- Between 19-59 years old
- Stable doses of regular medications
- Receive their transgender care from one of five(5) Vancouver-based physicians who specialize in transgender care (Three Bridges or Raven Song Community Health Centres).
Exclusion
- Medically or psychiatrically unstable
- Recent or imminent surgery (6-8 weeks) that has or may affect testosterone dosage
- Unable to present for nine(9) weeks of weekly blood work and two(2) weeks of alternate day blood work
Key Trial Info
Start Date :
July 1 2015
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2016
Estimated Enrollment :
14 Patients enrolled
Trial Details
Trial ID
NCT02229617
Start Date
July 1 2015
End Date
May 1 2016
Last Update
June 6 2016
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Three Bridges Community Health Centre
Vancouver, British Columbia, Canada, V6Z 1W2
2
Raven Song Community Health Centre
Vancouver, British Columbia, Canada